These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22695893)

  • 1. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.
    Boivin AA; Cardinal H; Barama A; Pichette V; Hébert MJ; Roger M
    Drug Metab Pharmacokinet; 2010; 25(5):508-15. PubMed ID: 20877131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO; Cho SK; Oh ES; Park MS; Chung JY
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
    Namgoong S; Cheong HS; Kim JO; Kim LH; Na HS; Koh IS; Chung MW; Shin HD
    Environ Toxicol Pharmacol; 2015 Nov; 40(3):692-7. PubMed ID: 26409184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
    Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
    Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
    Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
    Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
    Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
    Woo HI; Kim SR; Huh W; Ko JW; Lee SY
    Drug Des Devel Ther; 2017; 11():1135-1146. PubMed ID: 28435225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
    Sortica Vde A; Ojopi EB; Genro JP; Callegari-Jacques S; Ribeiro-Dos-Santos A; de Moraes MO; Romano-Silva MA; Pena SD; Suarez-Kurtz G; Hutz MH
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):460-8. PubMed ID: 22136368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
    Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
    Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
    Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
    Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
    Nassif A; Jia J; Keiser M; Oswald S; Modess C; Nagel S; Weitschies W; Hosten N; Siegmund W; Kühn JP
    Radiology; 2012 Sep; 264(3):741-50. PubMed ID: 22771883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
    Oh ES; Kim CO; Cho SK; Park MS; Chung JY
    Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.